Novartis AG ADR
USUSDNovartis AG ADR (SW:NOVN) — Drug Manufacturers - General. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 7. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Hauptsitz
- BASEL, Switzerland
- CEO
- Dr. Vasant Narasimhan M.D.
- Mitarbeiter
- 75 267
- Gegründet
- 1996
- Ausstehende Aktien
- 1.91 Mrd. Stand 2025-12-31
- Streubesitz
- 1.86 Mrd.
- Marktkapitalisierung
- 276.48 Mrd. USD
- Insider
- 0.01%
- Institutionelle Anleger
- 7.27%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Ausschüttungsquote
- 71.1%
- FCF
- 15.0 Mrd. USD61%
- Schulden
- 49.0 Mrd. USD2.6 J. FCF
- Dividendenserie
- 20 J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 30.06.2026 (letzter Bericht des Unternehmens).
Beschreibung
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | NVSEF OTC | USD | 134.22 -0.23% | Stammaktie |
| LSE London Stock Exchange | 0QLR IOB | CHF | 82.63 +0.00% | Stammaktie |
| MI Borsa Italiana (Milan) | 1NOVN zusätzlich | EUR | 125.88 -2.11% | Stammaktie |
| SW SIX Swiss Exchange | NOVN primär | CHF | 119.8 -0.13% | Stammaktie |
| SW SIX Swiss Exchange | NOVNEE zusätzlich | CHF | 120.02 -1.80% | Stammaktie |
| VI Vienna Stock Exchange | NOVN zusätzlich | EUR | 126.72 | Stammaktie |
| XETRA Xetra | NOT zusätzlich | EUR | 126.82 +0.48% | Stammaktie |
Dividenden
Novartis AG ADR (NOVN) zahlt einmal jährlich Dividenden. In den letzten 12 Monaten wurde 3.7 CHF pro Aktie gezahlt (Zahlungen: 1). Das entspricht etwa 3.09% des aktuellen Aktienkurses. Basierend auf der Zahlungshistorie wird der nächste Ex-Dividenden-Tag um den 15.03.2027 erwartet. Ununterbrochene Dividendengeschichte: 20 Jahre.
| Ex-Tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-03-10 | 2026-03-12 | 3.7000 CHF | 3.1/3.1 % | jährlich | SW:NOVN |
| 2025-03-11 | — | 3.5000 CHF | 2.9/2.9 % | jährlich | SW:NOVN |
| 2024-03-07 | — | 3.3000 CHF | 2.8/2.8 % | jährlich | SW:NOVN |
| 2023-03-09 | — | 3.2000 CHF | 2.7/2.7 % | jährlich | SW:NOVN |
| 2022-03-08 | — | 3.1000 CHF | 2.6/2.6 % | jährlich | SW:NOVN |
Neuigkeiten diese Woche
Noch keine Nachrichten von der Website des Unternehmens.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.35% | 27.43 Mio. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.9% | 18.24 Mio. | 2026-06-30 |
| Fisher Asset Management,… | 0.76% | 15.52 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 13.69 Mio. | 2026-08-31 |
| Goldman Sachs TRT II-Gol… | 0.6% | 12.19 Mio. | 2026-07-31 |
| Artisan Partners Funds I… | 0.51% | 10.29 Mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 0.44% | 8.9 Mio. | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 Mio. | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 Mio. | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 7.12 Mio. | 2026-07-31 |
| Primecap Management Comp… | 0.32% | 6.59 Mio. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 6.53 Mio. | 2026-08-31 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 Mio. | 2026-06-30 |
| MFS Series Trust XVII-MF… | 0.26% | 5.22 Mio. | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 Mio. | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.23% | 4.66 Mio. | 2026-07-31 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 Mio. | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 Mio. | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 Mio. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 Mio. | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 Mio. | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 Mio. | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 Mio. | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 Mio. | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 Mio. | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
| Pacer Advisors, Inc. | 0.02% | 482 153 | 2026-06-30 |
| Partners Capital Investm… | 0% | 24 335 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 21 514 | 2026-06-30 |
| Generali Investments Cee… | 0% | 15 729 | 2026-06-30 |
